Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study-Reference-Cited by-同舟云学术

Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study

Published:2021-07-23 Issue:12 Volume:61 Page:1555-1566
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Hurwitz Selwyn J.¹,Tao Sijia¹,Gavegnano Christina²,Jiang Yong¹,Tressler Randall L.³,Tsibris Athe⁴,del Rio Carlos⁵,Overton Edgar T.⁶,Lederman Michael M.⁷,Kantor Amy⁸,Moser Carlee⁸,Kohler James J.¹,Lennox Jeffrey⁹,Marconi Vincent C.¹⁰,Flexner Charles W.¹¹,Schinazi Raymond F.¹

Affiliation:

1. Laboratory of Biochemical Pharmacology Emory Center for AIDS Research Department of Pediatrics Emory University School of Medicine and Children's Healthcare of Atlanta Atlanta Georgia USA

2. Department of Pathology and Laboratory Medicine and Department of Pharmacology and Chemical Biology Emory University School of Medicine Atlanta Georgia USA

3. National Institutes of Health/National Institute of Allergy and Infectious Disease Rockville Maryland USA

4. Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

5. Department of Medicine and Hubert Department of Global Health Rollins School of Public Health Emory University Atlanta Georgia USA

6. Division of Infectious Diseases Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA

7. Case Western Reserve University School of Medicine and University Hospitals/Case Medical Center Cleveland Ohio USA

8. Harvard T.H. Chan School of Public Health Boston Massachusetts USA

9. Division of Infectious Diseases Emory University School of Medicine and Grady Memorial Hospital Atlanta Georgia USA

10. Division of Infectious Diseases Emory University School of Medicine and Rollins School of Public Health and Atlanta Veterans Affairs Medical Center Decatur Georgia USA

11. Divisions of Clinical Pharmacology and Infectious Diseases School of Medicine and Bloomberg School of Public Health Johns Hopkins University Baltimore Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1930

Reference31 articles.

1. JAKAFIi (ruxolitinib) tablets prescribing label ‐ U.S. FDA.https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf. Accessed September 29 2020.

2. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors

3. Randomized trial of ruxolitinib in antiretroviral‐treated adults with HIV [published online ahead of print March 6, 2021];Marconi VC;Clin Infect Dis

4. The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers

5. U.S. FDA W DC. 2011 Clinical pharmacology review of ruxolitinib (JAKAFIi™ Incyte) NDA/BLA Number 202192Orig1s000.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000ClinPharmR.pdf. Published June 2011. Accessed December 16 2020.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review;Clinical Pharmacokinetics;2023-03-31